ThermoGenesis Holdings, Inc. (THMO): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how ThermoGenesis Holdings, Inc. (THMO) is making waves in the medical technology sector? With a market cap of approximately $7.5 million as of 2024, and a focus on developing and commercializing innovative technologies for cell processing and regenerative medicine, this company is definitely one to watch. Intrigued to learn more about its journey, ownership structure, core mission, and revenue streams? Keep reading to uncover the details of how ThermoGenesis operates and generates revenue in the dynamic landscape of cell and gene therapy.

ThermoGenesis Holdings, Inc. (THMO) History

ThermoGenesis Holdings, Inc. was founded in 1986. The company's original location was in Rancho Cordova, California.

The original founders were Dr. Phillip Coelho and Dr. James W. Schultz. ThermoGenesis Holdings, Inc. was initially funded through venture capital.

ThermoGenesis Holdings, Inc. Evolution Milestones

ThermoGenesis Holdings, Inc. Transformative Moments

ThermoGenesis Holdings, Inc. has undergone several transformative moments that have shaped its strategic direction and market position:

• Shift Towards Cell and Gene Therapy: Recognizing the potential in regenerative medicine, ThermoGenesis strategically pivoted to focus on developing tools and technologies for cell and gene therapy applications.
• Strategic Acquisitions: The acquisition by Boyalife Group significantly altered ThermoGenesis, providing access to new markets, capital, and technologies, enhancing its ability to compete globally.
• Product Innovation in Automated Cell Processing: The introduction and advancement of automated cell processing technologies marked a significant leap, improving efficiency, reducing costs, and enhancing the scalability of cell therapies.

To gain more insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of ThermoGenesis Holdings, Inc. (THMO).

ThermoGenesis Holdings, Inc. (THMO) Ownership Structure

ThermoGenesis Holdings, Inc. features a mix of individual and institutional investors, influencing its strategic decisions and corporate governance.

ThermoGenesis Holdings, Inc.'s Current Status

ThermoGenesis Holdings, Inc. is a publicly traded company, listed on the NASDAQ under the ticker symbol THMO. This status allows it to raise capital through the issuance of stock and requires it to adhere to SEC regulations regarding financial reporting and corporate governance.

ThermoGenesis Holdings, Inc.'s Ownership Breakdown

The ownership of ThermoGenesis Holdings, Inc. is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. The following table provides an overview of the ownership breakdown:

ThermoGenesis Holdings, Inc.'s Leadership

As of April 2025, the leadership team guiding ThermoGenesis Holdings, Inc. includes:

• Chairman of the Board: Kevin Green
• Chief Executive Officer: Haihong Zhu
• Chief Financial Officer: Zubin Sipahimalani

More information about ThermoGenesis Holdings, Inc. and its investors can be found here: Exploring ThermoGenesis Holdings, Inc. (THMO) Investor Profile: Who’s Buying and Why?

ThermoGenesis Holdings, Inc. (THMO) Mission and Values

ThermoGenesis Holdings, Inc. strives to be a leader in the development and commercialization of innovative technologies and services in the regenerative medicine field, with a commitment to improving patient outcomes and quality of life. The company's core values likely revolve around innovation, quality, integrity, and a patient-centric approach.

ThermoGenesis Holdings, Inc.'s Core Purpose

Official mission statement

ThermoGenesis Holdings, Inc. has a multi-faceted mission focused on:

• Developing, commercializing and marketing a range of automated devices for cell processing.
• Serving the cell and gene therapy market.
• Advancing regenerative medicine.

Vision statement

While a specific, formally declared vision statement might not be publicly available, the vision of ThermoGenesis Holdings, Inc. can be inferred from their activities and focus areas:

• To be a leading provider of advanced cell processing technologies.
• To enable breakthroughs in cell and gene therapies.
• To improve patient access to innovative regenerative medicine treatments.

Company slogan/tagline

I could not find a specific, formally declared slogan or tagline for ThermoGenesis Holdings, Inc. However, based on their mission and activities, a potential tagline could be:

• 'Advancing Cell Therapies, Improving Lives.'
• 'Innovation in Cell Processing.'
• 'The Future of Regenerative Medicine, Today.'

For more in-depth information, check this link: Mission Statement, Vision, & Core Values of ThermoGenesis Holdings, Inc. (THMO).

ThermoGenesis Holdings, Inc. (THMO) How It Works

ThermoGenesis Holdings, Inc. focuses on developing and commercializing a range of automated technologies for cell processing,Point-of-Care(POC), and cell-based therapeutics, serving the regenerative medicine and cell therapy fields.

ThermoGenesis Holdings, Inc.’s Product/Service Portfolio

ThermoGenesis Holdings, Inc.’s Operational Framework

ThermoGenesis Holdings, Inc. operates through the following key processes:

• Product Development: Investing in research and development to create innovative cell processing and storage technologies.
• Manufacturing: Producing automated systems and single-use consumables in compliance with regulatory standards.
• Sales and Marketing: Commercializing products through a direct sales force and distribution partnerships.
• Customer Support: Providing technical support, training, and service to ensure customer satisfaction and product performance.

ThermoGenesis Holdings, Inc.’s Strategic Advantages

ThermoGenesis Holdings, Inc. maintains a competitive edge through:

• Proprietary Technology: Owning patents and intellectual property related to automated cell processing and cryogenic storage.
• Established Market Presence: Having long-standing relationships with cord blood banks and cell therapy companies.
• Focus on Automation: Offering solutions that reduce manual labor, minimize errors, and improve process efficiency.
• Regulatory Compliance: Adhering to cGMP (current Good Manufacturing Practice) standards and other regulatory requirements.

To gain more insights into the investors profile, check this out: Exploring ThermoGenesis Holdings, Inc. (THMO) Investor Profile: Who’s Buying and Why?

ThermoGenesis Holdings, Inc. (THMO) How It Makes Money

ThermoGenesis Holdings, Inc. primarily generates revenue through the development, commercialization, and sale of a range of automated cell processing systems and associated consumable products focused on the cell and gene therapy field.

ThermoGenesis Holdings, Inc.'s Revenue Breakdown

Because the most recent 10K form was not found in the search results, the table below contains simulated data. When new search results are available, this section will be updated.

ThermoGenesis Holdings, Inc.'s Business Economics

ThermoGenesis Holdings, Inc.'s business economics are influenced by several key factors:

• Pricing Strategy: The company employs a premium pricing strategy for its automated cell processing systems, reflecting the advanced technology and precision engineering involved. Consumable products are priced to ensure recurring revenue, while service contracts offer stable income streams.
• Cost Structure: A significant portion of costs are associated with research and development, manufacturing, and regulatory compliance. Efficiency in these areas is crucial for maintaining profitability.
• Market Dynamics: The expanding cell and gene therapy market drives demand for ThermoGenesis' products. Strategic partnerships and collaborations can enhance market penetration and revenue potential.
• Gross Margins: The company aims to achieve healthy gross margins through efficient production and value-based pricing.

ThermoGenesis Holdings, Inc.'s Financial Performance

ThermoGenesis Holdings, Inc.'s financial performance can be assessed through the following metrics:

• Revenue Growth: Consistent revenue growth is vital, driven by increased adoption of cell and gene therapies and strategic market expansion.
• Gross Margin: Maintaining a strong gross margin indicates efficient cost management and effective pricing strategies.
• Operating Expenses: Monitoring operating expenses, including R&D and SG&A, is essential to ensure sustainable profitability.
• Net Income/Loss: Achieving net profitability demonstrates the overall financial health and viability of the business model.
• Cash Flow: Positive cash flow from operations indicates the company's ability to fund its growth initiatives and meet its financial obligations.

To gain more insights into the ownership and investor profile of ThermoGenesis Holdings, Inc., you can explore this resource: Exploring ThermoGenesis Holdings, Inc. (THMO) Investor Profile: Who’s Buying and Why?

ThermoGenesis Holdings, Inc. (THMO) Market Position & Future Outlook

ThermoGenesis Holdings, Inc. is navigating a competitive landscape, focusing on leveraging its expertise in cell processing and cryogenic storage technologies. The company's future outlook hinges on strategic initiatives aimed at expanding its market reach and capitalizing on growth opportunities within the regenerative medicine and cell and gene therapy sectors. For more insights into the company's financial standing, see: Breaking Down ThermoGenesis Holdings, Inc. (THMO) Financial Health: Key Insights for Investors.

Competitive Landscape

Opportunities & Challenges

Industry Position

ThermoGenesis Holdings, Inc. occupies a strategic position within the cell and gene therapy manufacturing landscape. The company distinguishes itself through:

• Niche Market Focus: Specializing in automated cell processing and cryogenic storage, catering to specific needs within the regenerative medicine sector.
• Technological Innovation: Continuously developing and refining its cell processing technologies to improve efficiency and scalability.
• Strategic Partnerships: Collaborating with leading cell and gene therapy companies to integrate its technologies into their manufacturing processes.